Invention Grant
- Patent Title: Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
-
Application No.: US14967276Application Date: 2015-12-12
-
Publication No.: US09408839B2Publication Date: 2016-08-09
- Inventor: Christian Lavedan , Simona Volpi
- Applicant: Vanda Pharmaceuticals, Inc.
- Applicant Address: US DC Washington
- Assignee: Vanda Pharmaceuticals, Inc.
- Current Assignee: Vanda Pharmaceuticals, Inc.
- Current Assignee Address: US DC Washington
- Agency: Hoffman Warnick LLC
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; A61K31/454
Abstract:
The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
Public/Granted literature
- US20160166561A1 ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE Public/Granted day:2016-06-16
Information query
